Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cora N Sternberg

Showing results (191-200 of 357) with videos related to

Pageof 36
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 27, 2013
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapyStephen Harland, John Staffurth, Arturo Molina, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2022
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)Daniel J George, Neeraj Agarwal, Oliver Sartor, et al.
Prostate Cancer and Prostatic Diseases|September 14, 2021
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trialsBertrand F Tombal, Stephen J Freedland, Andrew J Armstrong, et al.
Clinical Genitourinary Cancer|January 25, 2023
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate CancerNobuaki Matsubara, Johann de Bono, Christopher Sweeney, et al.
BJU International|August 16, 2014
Enzalutamide in European and North American men participating in the AFFIRM trialAxel S Merseburger, Howard I Scher, Joaquim Bellmunt, et al.
JAMA Oncology|June 28, 2019
Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 StudyGerhardt Attard, Axel S Merseburger, Wiebke Arlt, et al.
World Journal of Urology|September 22, 2018
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancerAxel S Merseburger, Andrea B Apolo, Simon Chowdhury, et al.
Future Oncology (London, England)|January 29, 2019
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationaleViktor Grünwald, Thomas Powles, Toni K Choueiri, et al.
The Lancet. Oncology|July 5, 2012
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trialsHai T Tran, Yuan Liu, Amado J Zurita, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2013
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety updateCora N Sternberg, Robert E Hawkins, John Wagstaff, et al.
Pageof 36

Showing results (191-200 of 357) with videos related to

Sort By:
Pageof 36
European Journal of Cancer (Oxford, England : 1990)|August 27, 2013
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapyStephen Harland, John Staffurth, Arturo Molina, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2022
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)Daniel J George, Neeraj Agarwal, Oliver Sartor, et al.
Prostate Cancer and Prostatic Diseases|September 14, 2021
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trialsBertrand F Tombal, Stephen J Freedland, Andrew J Armstrong, et al.
Clinical Genitourinary Cancer|January 25, 2023
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate CancerNobuaki Matsubara, Johann de Bono, Christopher Sweeney, et al.
BJU International|August 16, 2014
Enzalutamide in European and North American men participating in the AFFIRM trialAxel S Merseburger, Howard I Scher, Joaquim Bellmunt, et al.
JAMA Oncology|June 28, 2019
Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 StudyGerhardt Attard, Axel S Merseburger, Wiebke Arlt, et al.
World Journal of Urology|September 22, 2018
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancerAxel S Merseburger, Andrea B Apolo, Simon Chowdhury, et al.
Future Oncology (London, England)|January 29, 2019
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationaleViktor Grünwald, Thomas Powles, Toni K Choueiri, et al.
The Lancet. Oncology|July 5, 2012
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trialsHai T Tran, Yuan Liu, Amado J Zurita, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2013
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety updateCora N Sternberg, Robert E Hawkins, John Wagstaff, et al.
Pageof 36